KPTI
Karyopharm TherapeuticsBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-03
+
Peers tracked
11
U.S. public peers
Grade Position
In line
vs peer average
KPTI vs peer average
69/100
KPTI vs. peer average (B vs. C)
Grade spread
A 2 · B 2 · C 1 · D 2 · F 3
Graded peers loaded
Coverage
11 graded
100% of tracked
Peer overview
ELDN is the first available peer comparator.
Eledon is a reasonable small-cap biotech risk-profile comp because clinical milestones and capital access drive valuation, even though the underlying programs differ materially from Karyopharm's oncology focus.
✓Peer source comes from the stored AI memo or peer model
✓Grades and factor rows use RankAlpha API data when available
✓Missing peer scores remain blank instead of being estimated
✓Side-by-side comparison keeps the data contract visible
KPTI
Karyopharm Therapeutics
ELDN
Eledon
Grade
B
D
Momentum
86
88
Value
41
41
Sentiment
40
0
Setup Bias
Net Neutral
-
Market Cap
-
-
Posture
Constructive
Defensive
Grade position vs ELDN
KPTI / ELDN
Grade Position
In line
KPTI vs. peer average (B vs. C)
69/100
Momentum
86
ELDNValue
41
KPTISentiment
40
KPTIRotation landscape
Peers ranked by the order returned from the peer source, with grades from the API.
Rank
Ticker
Company
Grade
Grade score
vs KPTI
ELDN is the first peer returned for this comparison set.